Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2023-04-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
2022年非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 85% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the year 2022 by 亿帆医药股份有限公司. It contains extensive financial data related to balances, interest, repayments, and relationships with subsidiaries and related parties. The content is financial and operational in nature but does not appear to be a full annual or interim report, nor an earnings release or audit report. It is a specific financial disclosure related to non-operating funds and related party transactions, which is typically part of regulatory disclosures or supplementary financial information. However, since it is a detailed financial summary with substantive data, it is not a mere announcement or certification. Given the nature of the data and the absence of broader financial statements or management discussion, the best fitting category is Regulatory Filings (RNS), as it is a regulatory disclosure document that does not fit into other more specific categories like Annual Report or Interim Report.
2023-04-14 Chinese
独立董事述职报告 （雷新途）
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report". It details the independent director's attendance at board meetings, opinions on various company matters including audit firm reappointment, employee stock plans, internal control reports, profit distribution proposals, and governance activities during the year 2022. The content focuses on the independent director's duties, opinions, and oversight activities rather than presenting full financial statements or comprehensive company financial performance. It is a report on the independent director's work and opinions related to governance and oversight, not an annual report, audit report, or earnings release. This type of document fits best under Board/Management Information (MANG) as it relates to board activities and management oversight. The document length (11,700 characters) and detailed content support this classification rather than a brief announcement or a full financial report.
2023-04-14 Chinese
2022年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from a company regarding its 2022 profit distribution plan, specifically stating that no profit distribution (dividends or stock bonuses) will be made for the year 2022. It includes detailed explanations about the legality, rationality, and reasons for not distributing profits, as well as the intended use of undistributed profits. The document also contains resolutions from the board of directors, supervisory board, and independent directors supporting the proposal, and mentions that the plan will be submitted to the 2022 annual shareholders meeting for approval. The document length is about 3,000 characters, which is relatively short and reads like an official announcement rather than a full financial report. It does not contain full financial statements or comprehensive financial analysis but rather focuses on the profit distribution proposal and related approvals. This fits the profile of a Notice of Dividend Amount or Dividend Distribution Announcement, even though the dividend amount is zero, because it is an official announcement about the profit distribution plan for the year. Therefore, the appropriate classification is Notice of Dividend Amount (DIV).
2023-04-14 Chinese
独立董事述职报告 （刘洪泉）
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report." It details the independent director's activities, opinions on board meetings, audit opinions, internal control evaluations, and governance oversight for the year 2022. The content focuses on the independent director's duties, opinions on company matters, attendance at meetings, and supervision of company governance and financial reporting. It is not a full annual report or audit report but a specific report by an independent director on their work and opinions during the year. This type of document is best classified under Board/Management Information (MANG) as it relates to management and board-level disclosures about director activities and governance oversight rather than financial results or regulatory filings. The document length and detailed content support this classification with high confidence.
2023-04-14 Chinese
关于变更会计政策的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding changes in accounting policies by the company 亿帆医药股份有限公司. It references specific accounting standards and interpretations issued by the Ministry of Finance of the People's Republic of China, detailing the nature and impact of these changes. The document does not contain financial statements or detailed financial data but rather explains the policy changes and their expected effects. The length is 4191 characters, which is relatively short and the content is focused on disclosure of accounting policy changes rather than a full financial report or audit. This fits the category of a Regulatory Filing (RNS), as it is a compliance announcement about accounting policy changes without substantive financial data or a full report attached.
2023-04-14 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2022" for a company, detailing the independent director's activities, opinions on board meetings, audit firm reappointment, internal control evaluation, employee stock ownership plans, and other governance-related matters during the year 2022. It includes detailed independent opinions on various corporate governance and financial matters, but it is not a full annual report or audit report itself. It is a formal report by an independent director on their duties and opinions, which is a type of management or governance report. Given the focus on the independent director's duties, opinions on governance, and oversight activities, this fits best under Board/Management Information (MANG). The document is substantive and not a mere announcement or certification, so it is not RNS or RPA. It is not a call transcript, earnings release, or other categories. Therefore, the best classification is MANG with high confidence.
2023-04-14 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.